|Articles|September 17, 0001
Side effects preclude thalidomide usefulness for AMD
Philadelphia-Thalidomide is dead, at least when it comes to itscurative properties for age-related macular degeneration (AMD). This isthe conclusion of the Age-Related Macular Degeneration and Thalidomide Study(AMDATS).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Metformin use associated with reduced incidence of intermediate AMD
2
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
3
Last year in glaucoma at EnVision Summit 2025
4
Looking back at the 2025 EnVision Summit
5
























